SUNNYVALE, Calif.--(BUSINESS WIRE)--EBR Systems, Inc., developer of WiSE™ (Wireless Stimulation Endocardially) which is the world’s first and only wireless cardiac pacing system for heart failure, was selected as Favorite Innovation category winner at the annual EUROPACE CARDIOSTIM congress in Milan, Italy.
The Cardiostim Innovation Awards are selected by an international panel of expert scientists and physicians from the European Heart Rhythm Association (EHRA) and presented during the opening ceremony of EHRA EUROPACE CARDIOSTIM.
EBR Systems’ WiCS®-LV (Wireless Cardiac Stimulation of the Left Ventricle) System is the world’s only leadless endocardial pacing system for cardiac resynchronization therapy (CRT). CRT is a treatment for heart failure that uses an implantable pacemaker to improve the pumping efficiency of the heart by synchronizing the left and right ventricles. Studies have demonstrated successful CRT therapy improves symptoms and reduces hospitalizations and mortality.
“We gratefully appreciate this award from luminaries in the European medical community,” said EBR Systems CEO Allan Will from the company’s Silicon Valley headquarters. “Heart failure affects 22 million people worldwide, including five million Americans. In fact, it’s the most costly disease in the US, estimated at more than $40 billion annually and growing. A growing body of evidence strongly suggests EBR’s wireless technology can benefit patients who have failed conventional cardiac resynchronization implants that use wire leads to transfer the electrical stimulation to the heart. We believe wireless pacing will become standard of care.”
CRT devices can improve left ventricular function and reduce morbidity and mortality in patients with cardiac synchronization problems. However, conventional CRT devices use wires to deliver pacing pulses to the left ventricle. These wires can break or otherwise fail, leading to complications in roughly 12% of cases.
In addition, approximately 30% of patients receiving conventional CRT do not respond to the therapy. A major reason for this is limitations on where wire leads can be placed in the heart’s venous anatomy.
In financial terms, that means more than one billion dollars of the $3.5 billion spent annually on CRT devices is wasted because they provide no patient benefit.
EBR Systems’ WiSE technology consists of an ultrasonic transmitter implanted in a space on the chest wall. The transmitter is connected to a battery implanted under the skin which is easy to replace. Together, they interact with a tiny electrode placed inside the heart’s left ventricular wall using a catheter.
This unique technology eliminates the need for leads and lets the physician place the stimulation point at the ideal location inside the left ventricle where it can be most effective. Data from multiple sources strongly suggests this can benefit patients and is a major advance in left ventricular stimulation.
WiSE technology also has potentially major implications for treating bradycardia, an abnormally slow or irregular heart rate. It can stimulate the left ventricle endocardially, instead of settling for the right ventricle, which is suboptimal.
About EBR Systems
EBR Systems is dedicated to superior treatment of cardiac rhythm disease by providing more physiologically effective pacing through wireless stimulation endocardially (WiSE). The company’s patented, proprietary technology was developed to eliminate the need for cardiac pacing leads, historically the major source of complications and reliability issues in cardiac rhythm disease management. The Company’s initial product eliminates the need for coronary sinus leads to stimulate the left ventricle in heart failure patients requiring CRT. Future products will address wireless endocardial stimulation for bradycardia and other non-cardiac indications.
The Company’s wireless pacing system is not currently available for commercial sale. The system is subject to the company obtaining a CE (Conformité Européenne) Mark for sale in Europe and approval for a U.S. IDE (Investigational Device Exemption) clinical study.